This Article Full Text Full Text (PDF) All Versions of this Article: 38/12/3310    most recent STROKEAHA.107.504613v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cockroft, K. M. Search for Related Content PubMed PubMed Citation Articles by Cockroft, K. M. Pubmed/NCBI databases Medline Plus Health Information Arteriovenous Malformations Related Collections Aneurysm, AVM, hematoma

(Stroke. 2007;38:3310.)
© 2007 American Heart Association, Inc.

Controversies in Stroke

Unruptured Brain Arteriovenous Malformations Should Be Treated Conservatively

No

From the Department of Neurosurgery, Penn State MS Hershey Medical Center, Hershey, Pa.

Correspondence to Kevin M. Cockroft, Department of Neurosurgery, Penn State MS Hershey Medical Center, PO Box 850, Hershey, PA 17033. E-mail kcockroft@psu.edu

Key Words: arteriovenous malformations • treatment

An extract of the first 250 words of the full text is provided, because this article has no abstract.

The case for treatment of asymptomatic cerebral arteriovenous malformations (AVM) is based on the premise that the morbidity and mortality of treatment should be less than the expected morbidity and mortality associated with the untreated AVM for the remainder of the patient’s expected lifetime—in other words the natural history of a treated AVM must be better than that of an untreated AVM. The literature contains a wide range of data on this subject, and by taking examples from across this spectrum one can easily support any viewpoint. Therefore, for the purposes of this discussion, published data from the Columbia AVM Databank will be used because this data are relatively "modern," are prospectively acquired and are frequently used to support a position of nonintervention for asymptomatic AVM.

For many years, intracranial AVM were generally considered to carry a bleed risk of about 2% per year for asymptomatic AVM and around 4% per year for symptomatic lesions, with each hemorrhage having an associated neurological morbidity of 20% to 30% and mortality of 10% to 30%.^1–6 Based on a combination of retrospective and prospective studies, sometimes without a clear distinction between symptomatic and asymptomatic AVM, and with some studies performed in the pre-MRI or pre-CT era, these numbers deserve careful examination and confirmation. Yet, although some recent studies have reported a dramatically lower mortality rate with AVM hemorrhage, the yearly hemorrhage rate and rate of morbidity were not found to be dramatically different. Using prospective data from the Columbia AVM Databank, Stapf et . . . [Full Text of this Article]